针对非胃肠层瘤软组织瘤的MAPK向治疗:目前的情况和未来的方向
Ouissam Al Jarroudi1,2, Khalid El Bairi3,4, Sami Aziz Brahmi1,2
1Department of Medical Oncology, Mohammed VI University Hospital, Oujda, Morocco.
Frontiers in oncology
|September 5, 2025
概括
这篇评论探讨了MAPK路径
科学领域:
- 癌症学
- 分子生物学
- 遗传学
背景情况:
- 非胃肠道瘤 (非GIST) 软组织肉瘤 (STS) 是具有有限治疗选择的侵袭性癌症.
- 了解STS的分子驱动因素对于开发向疗法至关重要.
- 甲基因激活蛋白激酶 (MAPK) 途径与肉瘤的发展有关.
研究的目的:
- 审查MAPK途径在非GIST STS中的作用.
- 研究MAPK抑制剂在STS治疗中的有效性.
- 突出针对MAPK途径的新兴治疗策略.
主要方法:
- 对非GIST STS中MAPK信号研究的文献综述.
- 分析涉及MAPK抑制剂的当前治疗模式.
- 对针对MAPK的新药的最新临床前和临床数据的评估.
主要成果:
- MAPK 途径对非GIST STS 发病有重要作用.
- 作为STS的向治疗方法,MAPK抑制剂具有前景.
- 组合疗法和新型分子药物正在研究中.
结论:
- 针对MAPK途径为非GIST STS提供了一个有前途的治疗途径.
- 需要进一步的转化和临床研究来确定生物标志物和优化治疗方法.
- 基于纳米材料的药物输送可以提高STS的治疗结果.
更多相关视频
07:15A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
Published on: July 28, 2020
9.7K
13:41Magnetic Resonance-Guided High Intensity Focused Ultrasound Generated Hyperthermia: A Feasible Treatment Method in a Murine Rhabdomyosarcoma Model
Published on: January 13, 2023
2.5K
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Drugs that Stabilize Microtubules
2.1K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Drugs that Destabilize Microtubules
2.0K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K
